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Case presentation
A 62-year-old white female was admitted to the New England
Medical Center for evaluation of hypercalcemia and renal insufficiency.
Ten years prior to admission, methyldopa was prescribed for hyperten-
sion. Serum creatinine was 1.3 mg/dl and serum calcium 10.8 mg/dl. Six
years prior to admission, she consumed approximately one quart of
milk every other day and three rolls of calcium carbonate tablets per
week for gastrointestinal upset. Radiographs of the upper gastrointes-
tinal tract revealed a hiatal hernia. Four years prior to admission, the
serum creatinine was 2.3 mg/dl and serum calcium 10.5 mg/dl.
Two months prior to admission, she was admitted to another hospital
because of weakness, polyuria, polydipsia, and constipation over
several months. Laboratory studies during that admission revealed a
white blood cell count of 16,000/mm3 with a normal differential,
hematocrit of 32%, and a platelet count of 419,000/mm3. The serum
calcium was 14 mg/dl; albumin was 4 g/dl. The phosphorus was 7.4
mg/dl; BUN, 72 mg/dl; serum creatinine, 6.7 mg/dl; sodium, 131
mEq/liter; potassium, 4.1 mEq/liter; chloride, 94 mEq/liter; and bicar-
bonate, 23 mEq/liter. The urine pH was 6.0 and the sediment cotitained
several granular casts. A 24—hour urine collection contained 330 mg of
protein. Parathyroid hormone (PTH) level, measured with antibody
against the N-terminal of the intact molecule, was 14 pg/mi (normal
range, 8—24 pg/mi). The 1,25 (OH)2 vitamin D level was 7 pg/mi (normal
range, 22—57 pg/mI). Thyroid function tests, serum and urine im-
munoelectrophoresis, bone scan, and bone marrow aspirate and biopsy
were normal. An abdominal plain film revealed no evidence of uephro-
Presentation of this Forum is made possible by grants from Merck
Sharp & Dohme; Sandoz, Incorporated; E. R. Squibb and Sons, mc;
and Pfizer Laboratories.
© 197 by the International Society of Nephrology
calcinosis; renal ultrasound disclosed small kidneys bilaterally, each
containing several simple cysts. A computerized tomographic scan of
the abdomen showed a solid-appearing mass in the right kidney and a
left adnexal mass. Open biopsy of the latter revealed a benign cystic
fibroadenoma. Mammography disclosed a calcium-containing nodule in
the right breast. Excislonal biopsy proved the lesion to be a benign
fibroadenoma.
The patient was treated with intravenous saline, furosemide, mithramy-
cm, aluminum hydroxide antacids, and prednisone (60 mg/day). At the
time of her discharge one month later, the BUN was 57 mg/dl; serum
creatinine, 4.5 mg/dl; and serum calcium, 10.0 mg/dl.
Several days after discharge she was readmitted to the same hospital
complaining of lightheadedness. The serum calcium was 13 mg/dl and
again responded to the same therapeutic measures. The patient was
subsequently transferred to this hospital for further evaluation.
Additional history obtained from the patient and her family included
a greater-than-20-year history of headaches for which she had intermit-
tently consumed phenacetin-containing compounds and, most recently,
a combination of propoxyphene, 65 mg, and acetaminophen, 650 mg, at
a dose of one to two tablets daily. Polyuria, polydipsia, and nocturia
had been present for more than 10 years. There was no history of renal
stones, urinary tract infection, diabetes mellitus, or vitamin D use.
Medications on admission included methyldopa, cimetidine, aluminum
hydroxide, and prednisone. Her vital signs were normal, as was her
general physical examination.
Laboratory evaluation revealed normal serum electrolytes; BUN, 88
mg/dl; serum creatinine, 4.6 mg/dl; and blood glucose, 70 mg/dl. The
serum calcium was 10.4 mg/dl; albumin, 3.9 g/dl; phosphorus, 5.3 mg/dl;
and alkaline phosphatase, 76 lU/liter. Urinalysis revealed: specific
gravity, 1.010; pH, 6.5; a negative dipstick; and 2 to 5 white blood
cells/high-power field. The C-terminal and mid-molecule PTH level was
4795 pg/mi (normal, 50—330 pg/mI), and the N-terminal PTH level was
33 pg/mI (normal, 8—24 pg/mI).
Radiographs of the chest and hands were normal. A sonogram of the
neck revealed multiple bilateral hypoechoic but solid-appearing masses
within the thyroid gland consistent with hyperplastic parathyroid glands. A
mass in the left lower pole suggesting either a thyroid or parathyroid
adenoma also was noted. Investigation of the previously noted right
kidney mass included a renal arteriogram, which revealed no evidence
of neoplastic disease.
The patient was subsequently discharged and methyldopa, aluminum
hydroxide, and prednisone, 30 mg daily, were prescribed. At time of
discharge, laboratory studies revealed a serum calcium of 9.0 mg/dl;
phosphorus, 3.7 mg/dl; and erum creatinine, 4.1 mgldl. Over the
ensuing 3 months, the serum calcium ranged between 9.9 and 10.8
mg/dl, and the serum creatinine progressively rose to 5.8 mg/dl. The
C-terminal PTH level was 1475 pg/mi (simultaneous calcium, 9.9 mg/dl).
In view of her history, recurrent hypercalcemia, desire to discontinue
taking prednisone, and concern about a possible parathyroid adenoma,
the patient underwent exploratory surgery of the neck. The preopera-
tive calcium level was 11.0 mg/dl. At operation, four enlarged parathy-
roid glands were noted and a subtotal parathyroidectomy was per-
formed.
Pathologic examination confirmed diffuse hyperplasia. No adenoma
was found. One month postoperatively, the serum calcium was 9.6
mg/dl; phosphorus, 4,0 mg/dl; C-terminal PTH, 579 pg/mi; and N-
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Fig. 1. Schematic representation of the formation of previtamin D3 in the skin during exposure to the sun and the thermal isomerization of pre-D3
to vitamin D3, which is specifically translocated by the vitamin D-binding protein (DBP) into the circulation. During continual exposure to the sun,
previtamin D3 also photoisomerizes to lumisterol3 and tachysterol3, which are photoproducts that are biologically inert (i.e., they do not stimulate
intestinal calcium absorption). Because the DBP has no affinity for lumisterol3 but has minimal affinity for tachysterol3, the translocation of these
photoisomers into the circulation is negligible, and these photoproducts are sloughed off during the natural turnover of the skin. Because these
photoisomers are in a state of quasiphotoequilibrium as soon as previtamin D3 stores are depleted (owing to thermal isomerization to D3), exposure
of lumisterol and tachysterol to ultraviolet radiation will provoke these isomers to photoisomerize to pre-D3. (From Ref. 4.)
terminal PTH, 14 pg/ml. The serum creatinine was 6.0 mg/dl. The
prednisone dose was 10 mg daily,
Discussion
Dr. MICHAEL F. HOLICK (Director, Vitamin D and Bone
Metabolism Laboratory, United States Department of Agricul-
ture/Human Nutrition Research Center; and Professor of Medi-
cine, Physiology, and Nutrition, Tufts University School of Med-
icine, Boston, Massachusetts): This 62-year-old white woman,
who had a greater-than.-20-year history of intermittent use of
phenacetin for the control of headache, went to another hospital
2 months before this admission with multiple complaints. The
workup revealed, among other blood chemistry abnormalities,
hypercalcemia, hyperphosphatemia, and moderate renal fail-
ure. Circulating concentrations of N-terminal parathyroid hor-
mone and 1,25-dihydroxyvitamin D were normal and low,
respectively. She responded to treatment—a combination of
diuresis, mithramycin, aluminum hydroxide, and prednisone—
and was discharged with a normal serum calcium and moderate
improvement in renal function. She returned 3 days later,
however, with a serum calcium of 13 mg/dl and was transferred
to the New England Medical Center. Evaluation revealed mild
hypercalcemia and hyperphosphatemia with a mid-molecule
and N-terminal parathyroid hormone concentration of greater
than 10 and 1.4 times above normal, respectively. Surgical
evaluation of the parathyroid glands resulted in a subtotal
parathyroidectomy and a pathologic diagnosis of diffuse hyper-
plasia.
Certainly multiple issues can be the focus of discussion in this
patient. But I will focus my attention on the important and
intimate relation that the kidney has with vitamin D* metabo-
lism and how perturbations in this relation can lead to a variety
of disorders of calcium metabolism and metabolic bone disease.
Historic perspective
As early as 1833, Lucas recognized the association between
chronic renal disease and the development of a bone disease
th4t was similar to rickets [1]. The defective skeletal mineral-
ization in azotemic children and adults was found by Liu and
Chu to be histologically indistinguishable from the osteopathy
of simple vitamin D deficiency [2]. They concluded that uremia
might interfere with the action of vitamin D. Indeed, metabolic
studies revealed that patients with chronic renal failure had
intestinal malabsorption of calcium consistent with vitamin D
deficiency [21. These authors further noted that physiologic
doses of vitamin D were ineffective in correcting this distur-
bance in calcium metabolism, and suggested that uremia caused
a resistance to vitamin D's action on the intestine and bone.
Pharmacologic doses of vitamin D often corrected these abnor-
malities [2]. Not until the late 1960s and early 1970s, with the
revelation that vitamin D required sequential hydroxylation in
the liver and kidney before it could perform its physiologic
actions on calcium and bone metabolism, was it clear why
patients with renal failure often had a resistance to vitamin D.
The purpose of this presentation will be to review the impact of
this and other advances in the vitamin D field as they relate to
calcium and bone metabolism and to cellular differentiation.
*Use of the term vitamin D without a subscript represents either
vitamin D2 or vitamin D3.
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Cutaneous production of vitamin D in humans
In 1921 Hess and Unger exposed rachitic children to sunlight
over several months and demonstrated for the first time that
exposure to sunlight could cure rickets [3]. It is now appreci-
ated that when human skin is exposed to sunlight, 7—dehydro-
cholesterol (provitamin D3) in the epidermis undergoes a pho-
tochemical reaction and gives rise to previtamin D3 [4] (Fig. 1).
This thermally labile intermediate undergoes a thermal isomer-
ization in the epidermis that requires 2 to 3 days to reach
completion. Once vitamin D3 is formed, the vitamin D-binding
protein in the dermal capillary circulation helps translocate
vitamin D3 from bloodless epidermal tissue into the circulation
(Fig. 1).
In the 1960s, Loomis popularized the theory that skin pig-
mentation evolved for the control of vitamin D production in
the skin [5]. Excessive exposure of light-skinned Causasoids to
sunlight does not cause vitamin D intoxication, however. A
more fundamental process regulates the cutaneous photosyn-
thesis of previtamin D3. Surgically obtained skin specimens
from Caucasoids and blacks were exposed to a simulation of
solar radiation that reaches the Earth in June at sea level at the
equator. An analysis of lipid extracts from the epidermis of the
Caucasoids revealed that, during the first 10 to 15 minutes of
exposure, approximately 15% of the provitamin D3 photolyzed
to previtamin D3 [6] (Fig. 2). Longer exposure, however, did
not significantly increase the production of previtamin D3. Alter
one hour of exposure, approximately 40% of provitamin D3 had
photolyzed, yet an analysis of the lipid extract from the stratum
basale revealed that only 15% of the photolyzed provitamin D3
was present as previtamin D3. The other 25% of the photolyzed
provitamin D3 was accounted for by the presence of lumisterol
and tachysterol (Figs. 1, 2). Further exposure continued to
deplete the stores of provitamin D3 in the epidermis but did not
increase the stores of previtamin D3. Instead, the lumisterol
concentrations continued to increase (Fig. 2). When black skin
specimens were exposed to the same conditions, longer expo-
sure times were needed to convert provitamin D3 to previtamin
D3. As skin pigmentation increased from type III to types V and
VI (skin type refers to the solar sensitivity of the skin; see Ref.
6 for details), the exposure time necessary to convert about 15%
of provitamin D3 to previtamin D3 increased from 30 minutes to
1 hour and 3 hours, respectively [6]. Other factors as well as
melanin pigmentation can regulate the production of vitamin D3
in the skin. An inverse correlation exists between aging and the
concentration of provitamin D3 in the epidermis [7] (Fig. 3).
When healthy volunteers (ages 20 to 30 years and 60 to 80 years)
were exposed to the same amount of simulated sunlight, circu-
lating concentrations of vitamin D3 in the younger volunteers
rose 2 to 3 times as high as did those in the older volunteers
(Matsuoka L, Wortsman J, Holick MF, unpublished results).
Sunscreens absorb the radiation responsible for inducing sun-
burn, the same radiation (290 to 315 nm) responsible for the
cutaneous photosynthesis of previtamin D3 [8, 9]. In fact, we
found that the topical application of a sunscreen with a sun
protection factor of 8 completely prevents the photosynthesis of
previtamin D3 in human skin [9].
Because multiple factors influence the production of vitamin
D3 in the skin, the amount of exposure to sunlight needed for
providing adequate vitamin D nutrition when sufficient amounts
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Fig. 2. High-performance liquid chromatography profiles of a lipid
extract from the basal cells of surgically obtained hypopigmented skin
that was previously shielded from (A) or exposed to (R-D) equatorial
simulated solar ultraviolet radiation for 10 miii (B), 1 hr (C), or 3 hr (D).
E, an analysis of the photolysis of 7-dehydrocholesterol (7-DHC) is the
basal cells and the appearance of the photoproducts previtamin D3
(pre-D3), lumisterol (L), and tachysterol (T) with increasing time of
exposure to equatorial simulated sunlight. (From Ref. 6; copyright 1981
by the American Association for the Advancement of Science.)
of vitamin D are not obtained from the diet will vary. The
amount of provitamin D3 that is photolyzed to previtamin D3 in
the skin depends on (1) how much surface area is exposed to
sunlight, (2) the amount of melanin in the skin (melanin absorbs
the solar radiation that is responsible for previtamin D3 synthe-
sis), (3) the time of day (around noon—il am to 2 pm—solar
radiation is the most intense), (4) latitude (the closer to the
equator, the greater the intensity of high-energy solar ultravio-
let radiation), and (5) the season (in the winter, compared with
other seasons, less solar ultraviolet radiation penetrates to the
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Earth's surface) [10]. People have assumed that the longer the
exposure of the skin to sunlight, the greater the cutaneous
production of vitamin D3. As I said, this assumption is not
necessarily correct, because solar radiation can isomerize pre-
vitamin D3 to biologically inactive isomers including lumisterol
and tachysterol (Figs. 1 and 2). In addition, vitamin D3,
exquisitely sensitive to sunlight, is photodegraded to 5,6-trans-
vitamin D3, suprasterol 1, and suprasterol 2 [111.
For light-skinned people who rely on sunlight for part or most
of their vitamin D, only short exposures to sunlight are needed
in the summer to adequately promote sufficient production of
vitamin D3. We have estimated that when young adults expose
their bodies to sunlight long enough to produce mild erythema,
they raise the circulating concentration of vitamin D3 about
fiftyfold, or the equivalent of ingesting approximately 10,000
IU, or 250 p.g, of vitamin D3. According to these data, for
whites in Boston in the summer, exposure of the hands, arms,
and face to suberythemal doses of sunshine (10 to 15 minutes,
depending on the person's skin pigmentation) on only 2 or 3
clear days weekly is enough to synthesize adequate amounts of
vitamin D3 [10]. People who want to remain outdoors after this
initial exposure but who are concerned about the harmful
effects of sunlight should use a sunscreen after the "adequate"
exposure [10]. Hollis and coworkers suggested that patients
with chronic renal failure are unable to produce vitamin D3 in
the skin, even though they have the same concentrations of
provitamin D3 in the epidermis as do age-matched controls [121.
Indeed, we have found that the dose of radiation required to
elicit a minimal erythematous response in patients with chronic
renal failure is 2 to 4 times that required for healthy age- and
skin pigment-matched controls. It appears that one or more
substances in the epidermis of patients with chronic renal
failure act like melanin and absorb the radiation that is respon-
sible for photolyzing epidermal stores of provitamin D3 to
previtamin D3 (Canzanello VJ, Palmer L, Madias NE, Holick
MF, unpublished results).
Metabolism of vitamin D
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Fig. 3. Effect of aging on 7—dehydrocholesterol concentrations in
human epidermis and dermis. Concentrations of 7-dehydrocholesterol
(provitamin D3) per unit area of human epidermis (•), stratum basale
[A], and dermis [01 obtained from surgical specimens from donors of
various ages. A lineal regression analysis revealed slopes of —0.05,
—0.06, and —0.0005 for the epidermis (r =
—0.89), stratum basale (r =
—0.92), and dermis (r = —0.04), respectively. The slopes of the
epidermis and the stratum basale are significantly different from the
slope of the dermis (P < 0.001). (From Ref. 7).
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After vitamin D3 is synthesized in the skin, it enters the
circulation bound to the vitamin D-binding protein, or it is
absorbed from the diet (as either vitamin D2 or vitamin D3) and
enters the circulation via the lymphatic system. It then is
transported to the liver, where it is metabolized by a vitamin—
D-25-hydroxylase to form 25-hydroxyvitamin D (25-OH-D) [13,
14] (Fig. 4). The vitamin-D-25-hydroxylase is located in the
mitochondria and microsomal fractions of the hepatic cells, and
the enzymatic reaction is supported by reduced NADP and
molecular oxygen [141. This enzyme does not appear to be
tightly regulated, inasmuch as the circulating 25-OH-D concen-
trations correlate with dietary vitamin D intake and environ-
mental exposure to sunlight [10, 15]. The liver is very important
in maintaining adequate circulating concentrations of 25-OH-D.
Although reports have surfaced about extrahepatic vitamin-D-
25-hydroxylases in chicks and rats [16, 17], there is no evidence
that these hydroxylases are operative in humans. The reserve
capacity of the vitamin D-25-hydroxylase in the liver is substan-
tial. Severe parenchymal or cholestatic liver disease is required
to lower circulating concentrations of 25-OH-D [181, but only
partly because of the decreased capacity of the severely dis-
eased liver to produce 25-OH-D. The low circulating concen-
trations of 25-OH-D also could be due to a reduction in the
intestinal absorption of vitamin D because of associated intes-
tinal fat malabsorption. Low circulating concentrations of 25-
OH-D do not, however, correlate with hepatic osteodystrophy
in patients with severe liver disease [18]. Although it is impor-
tant that one maintain adequate vitamin D nutrition in these
patients, either by increasing the oral administration of vitamin
D or by instituting parenteral nutrition, there is no evidence that
25-OH-D or vitamin D metabolite treatment significantly affects
bone disease in patients with chronic hepatic failure [19].
Several mechanisms, other than severe chronic liver disease,
also reduce serum 25-OH-D concentrations. Patients with ne-
phrotic syndrome who have marked proteinuria (greater than 4
g/24 hours) also can have decreased concentrations of 25-OH-D
in the circulation as a result of a urinary loss of the vitamin
D-binding protein (which is similar in molecular weight to
albumin) with its tightly bound 25-OH-D [20].
Patients taking anticonvulsant drugs can develop vitamin
D-resistant osteomalacia or rickets [21, 22]. Clinical evaluation
of these patients often demonstrates hypocalcemia, secondary
hyperparathyroidism, and an elevated alkaline phosphatase.
The hallmark for this disorder is low circulating concentrations
of 25-OH-D [23]. Although the exact mechanism for anticon-
vulsant-drug-induced vitamin D resistance is not completely
understood, it is known that phenytoin and phenobarbital
disrupt calcium homeostasis by inhibiting intestinal calcium
absorption by both vitamin D-dependent and -independent
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mechanisms. Phenobarbital stimulates bile secretion, thereby
increasing the turnover of vitamin D, and it inhibits the biologic
effects of parathyroid hormone on bone [24]. These patients
often are easily managed by increasing their intake of vitamin D
from 400 IU to 4000 IU daily. An alternative is to provide these
individuals with a 50,000 unit capsule of vitamin D2 once or
twice weekly and to carefully monitor the serum calcium and
25-OH-D concentrations. Raising the circulating concentration
Fig. 4. The photochemical, thermal, and
metabolic pathways for vitamin D3. Circled
letters and numbers denote specific enzymes:
0 7- dehydrocholesterol reductase; ® =
vitamin- D-25—hydroxylase; In =
25-OH-D-la-hydroxylase; =
25-OH-D-24R-hydroxyiase; = 25-OH-D-26-
hydroxylase. (From Ref. 23.)
of 25-OH-D to normal levels usually results in resolution of the
bone disease, and the serum calcium concentration generally
returns to normal. This disorder appears to be more prevalent in
institutionalized individuals (who do not receive adequate sun
exposure) who are taking multiple drugs for seizure control. A
study that evaluated several hundred patients who had taken
300 mg of phenytoin for 2 years revealed that their 25-OH-D
levels remained normal [25]. Deleterious effects of these anti-
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convulsant drugs on calcium and bone metabolism therefore are
of clinical concern only in patients who are taking multiple
antiseizure medications and who have poor vitamin D nutrition
either because of minimal vitamin D intake or limited exposure
to the sun.
Renal metabolism of 25-hydroxyvitamin D to
1,25-dihydroxyvitamin D
Although it was recognized in the 1940s that patients with
severe renal failure had a resistance to vitamin D, it was not
until 1970, when Fraser and Kodicek reported that homoge-
nates of chicken kidney could metabolize 25-OH-D3 to a
biologically active metabolite [26], that the intimate relationship
between the kidney and vitamin D first became apparent. It was
quickly demonstrated that 25-OH-D3 at physiologic concentra-
tions could not stimulate either intestinal calcium transport or
bone calcium mobilization in anephric rats [27]. These obser-
vations provided the impetus for the intense effort that led to
the isolation and structural identification of the renal metabolite
of 25-OH-D3 as 1 ,25-dihydroxyvitamin D3 [l,25(OH)2D3] [28,
29] (Fig. 4). It is generally believed that the l,25-dihydroxy
metabolite of vitamin D2 and D3 is the biologically active form
of vitamin D2 and vitamin D3, respectively. This metabolite is
approximately 10 times more active on a weight basis than is
vitamin D in healing rickets, stimulating intestinal calcium
absorption, and mobilizing calcium from the bone in rats [14].
The renal 25-OH-D-la-hydroxylase, a mitochondrial cyto-
chrome P-450 mixed-function oxidase, requires NADPH and
molecular oxygen for its activity [301. Although the exact
location of this enzyme in the human kidney is unknown, it is
likely that, as in rats [31], it is in the proximal convoluted
tubules. Originally it was surmised that, because vitamin D is a
calcium-regulating hormone, circulating concentrations of cal-
cium would direct the activity of 25-OH-D-l a-hydroxylase.
This hypothesis was supported by observations that hypocal-
cemic vitamin D-deficient rats could more efficiently metabolize
25-OH-D3 to 1 ,25(OH)2D3 than could normocalcemic vitamin
D-sufficient animals [32]. When vitamin D-deficient hypocalce-
mic rats were thyroparathyroidectomized (TPTX), however,
the metabolism of 25-OH-D3 to 1 ,25(OH)2D3 markedly dimin-
ished [33]. Renal production of 1 ,25(OH)2D3 was restored when
the animals received PTH [331. To further evaluate the role of
PTH, calcium, and phosphorus on 25-OH-D metabolism, circu-
lating concentrations of calcium and phosphorus in TPTX rats
were altered by manipulation of dietary calcium and phospho-
rus. Animals maintained on a high-calcium, low-phosphorus
diet efficiently metabolized 25-OH-D3 to 1 ,25(OH)2D3 despite
the absence of PTH [14]. This ability suggested that PTH
indirectly influenced the 25-OH-D- 1 cs-hydroxylase through its
effect on phosphate metabolism. Similar observations have
been made in humans [34]. In healthy men, phosphorus restric-
tion caused an increase in circulating concentrations of
1 ,25(OH)2D3 to 80% above control values, whereas phosphorus
supplementation produced an abrupt decrease to levels that
were 29% lower than those measured when the phosphorus
intake was normal [34]. These and other observations have led
to the conclusion that a small decrease in ionized calcium
promptly increases PTH secretion by the parathyroid glands.
Parathyroid hormone travels to the kidney and increases tubu-
VITAMIN DI
Parathyroid sI1:,e
PO4
Fig. 5. Schematic representation of the hormonal control loop for
vitamin D metabolism and function. A reduction in the serum calcium
below approximately 8.8 mg/100 ml serum prompts a proportional
secretion of parathyroid hormone that acts to mobilize calcium stores
from the bone. Parathyroid hormone also promotes the synthesis of
1,25(OH)2D in kidney, which, in turn, stimulates the mobilization of
calcium from bone and intestine.
lar reabsorption of calcium and excretion of phosphorus [23].
The attendent decrease in intracellular phosphorus is believed
to be the mechanism that triggers increased renal mitochondrial
production of 1 ,25(OH)2D3; 1 ,25(OH)2D3 travels to the small
intestine, where it increases intestinal calcium absorption [14]
(Fig. 5). It also is transported to the bone where, in concert with
PTH, it stimulates calcium resorption [14, 23] (Fig. 5). I should
note, however, that PTH is not absolutely essential for the renal
production of l,25(OH)2D, inasmuch as patients with hypopa-
rathyroidism often have low-normal circulating concentrations
of 1 ,25(OH)2D [23]. It is likely that PTH is an important sentry
that modulates the renal production of 1,25(OH)2D.
Alternate renal metabolic pathways for
25-hydroxyvitamnin D3
The kidney possesses a variety of enzymes that can trans-
form 25-OH-D3 into innumerable dihydroxy, trihydroxy, and
tetrahydroxy metabolites [14, 23, 35, 36]. During the early
investigations into 25-OH-D3 metabolism, it was observed that
when vitamin D-deficient rats were given supplemental vitamin
Liver D-25-
P04 and
OTHER FACTORS
1 ,25-(OH)2-D
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D, serum concentrations of calcium and phosphorus were
corrected to normal, and the rats hydroxylated 25-OH-D3 at
C-24 to form 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] [32,
37] (Fig. 4). The major circulating dihydroxy metabolite of
25-OH-D is 24,25(OH)2D, and its concentrations are a reflection
of 25-OH-D concentrations [23]. Although the kidney is the
primary site for its production, most other tissues that possess
nuclear receptors for 1 ,25(OH)2D also have the enzymatic
machinery to produce 24,25-(OH)2D [35, 38, 39]. Originally the
activities of the renal 25-OH-D-24- and 1 a-hydroxylases were
thought to be intimately linked so that the stimulation of one
automatically inhibited the other's activity, and vice versa. It
now appears, however, that these mitochondrial enzymes are
unrelated. The factor that links these two enzymes is 1 ,25(OH)2D,
which not only stimulates the 25-OH-D-24-hydroxylase to in-
crease the production of 24,25(OH)2D, but also inhibits the
activity of 25-OH-D- 1 a-hydroxylase [14, 23, 36, 38].
Controversy remains about whether 24,25(OH)2D has a phys-
iologic role in calcium and bone metabolism. This metabolite
can (1) increase bone formation in chicks [40], (2) induce
proteoglycan synthesis in cultured growth-plate chondrocytes
[41], (3) improve calcium retention in anephric patients [42],
and [4] promote bone mineralization in humans, when com-
bined with 1 ,25(OH)2D3, to a greater degree than 1 ,25(OH)2D3
could by itself [43]. As intriguing as these results appear, other
evidence suggests that 24,25(OH)2D3 is not physiologically
important for calcium and bone metabolism. At physiologic
concentrations, 24,25(OH)2D3 is about as active as 25-OH-D3 in
stimulating intestinal calcium transport and bone calcium mo-
bilization in vitamin D-deficient rats [14, 38]. Furthermore, the
biologic activity of 24,25(OH)2D3 most likely is due to its renal
metabolism to lct,24,25-trihydroxyvitamin D3 [1 ,24,25(OH)3D3],
as 24,25(OH)2D3 is biologically inert in anephric vitamin D-
deficient rats [14, 44]. In addition, the 24,24' difluoro derivative
of 25-OH-D3 [an analogue of 25-OH-D3 in which both of the
hydrogens are replaced by fluorines, thus preventing 25-OH-D3
from being hydroxylated at C-24 to form 24,25(OH)2D3] has the
same biologic activity as 25-OH-D1 in increasing intestinal
calcium transport, stimulating bone calcium mobilization, and
promoting bone mineralization [45]. The kidney also can me-
tabolize 25-OH-D3 at either C-23 or C-26 to produce 23,25-
dihydroxyvitamin D3 and 25,26-dihydroxyvitamin D3, respec-
tively [14, 35, 36, 38] (Fig. 6). Like 24,25(OH)2D3, these
metabolites can act as a substrate for the renal 25-OH-D-1-
hydroxylase to form 1 ,23,25-trihydroxyvitamin D3 and 1,25,26-
trihydroxyvitamin D3 [35, 36]. A multitude of other hydroxyla-
tions and oxidations can occur in the side chain of 25-OH-D3
and its dihydroxymetabolites [14, 35, 36, 38]. One of the more
unusual renal metabolites of 25-OH-D3 is 25-hydroxyvitamin
D3-23,26-lactone [14, 35, 36, 38] (Fig. 6). This metabolite is only
detectable in the serum of humans and rats that have received
pharmacologic doses of vitamin D. Although this metabolite
does not have any vitamin D-like biologic activity [14], it is
curious that the vitamin D-binding protein binds to it with 5
times greater affinity than it binds to 25-OH-D3 [35]. Although
more than two dozen metabolites of vitamin D have been
identified to date, none of these metabolites is either more active
or has unique biologic properties distinct from 1 ,25(OH)2D3. It is
believed that the purpose of the majority of the side-chain
hydroxylations is to degrade 25-OH-D and its hydroxylated
metabolites. This is particularly true of the C-23 and C-24
hydroxylations, which ultimately give rise to the biologically
inactive, water-soluble metabolite 1 a-hydroxy-24,25,26,27-te-
tranor-23-carboxylic acid-vitamin D3 [14, 35, 36, 38].
External metabolism of 25-hydroxyvitamin D3 to
1 ,25-dihydroxyvitamin D3
The kidney is the principal, if not sole, source of 1 ,25(OH)2D
in mammals and in healthy, nonpregnant humans. Animal
studies have shown that 24 hours after an intravenous injection
of 3H-25-OH-D3, 3H-l ,25(OH)2D3 can be detected in the blood,
intestine, bone, kidney, and a variety of other tissues in
vitamin-D deficient rats [46], whereas no 3H- 1 ,25(OH)2D3 was
found in vitamin-D deficient rats that had undergone bilateral
nephrectomy before receiving 3H-25-OH-D3 [46]. Patients who
have had bilateral nephrectomy or who have severe renal
failure usually have very low or undetectable circulating con-
centrations of I ,25(OH)2D [23, 38, 47].
The first evidence that extrarenal sites were capable of
metabolizing 25-OH-D3 to 1 ,25(OH)2D3 was found in pregnant
rats. Bilateral nephrectomy reduced but did not eliminate the
metabolism of 3H-25-OH-D3 to 3H- 1 ,25(OH)2D3 in pregnant rats
[48, 491. In-vitro studies have confirmed that the placenta is a
major site for 1 ,25(OH)2D synthesis during pregnancy [50—52].
Other circumstances also exist in which 25-OH-D3 is metabo-
lized to 1 ,25(OH)2D3 without the aid of the kidney. In vitro, a
wide variety of cultured cells from chick embryonic calvaria
[531, normal human bone [54], human melanoma [55], human
osteosarcoma [56], and neonatal keratinocytes [57] have the
25-OH-D3
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Fig. 6. Pathway of 25-OH-D3 metabolism to 25-OH-D3-26,23-lactone.
(From Ref. 35.)
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Fig. 7. Relation of changes in serum levels of J,25(OH)2D, iPTH, and
calcium to doses of prednisone administered to control hypercalcemia.
The solid portion of the bar representing the administration of predni-
sone indicates daily therapy, and the open portion indicates alternate-
day therapy. Bx denotes biopsy. To convert values for 1 ,25(OH)2D to
picomoles per liter, multiply by 2.36. To convert values for calcium to
millimoles per liter, multiply by 0.25. (From Ref. 59.)
enzymatic machinery to convert 25-OH-D3 to l,25(OH)2D3.
These cells also produce 24,25-(OH)2D3 when 1 ,25(OH)2D3 is
added to the culture. These in-vitro studies have led some
investigators to conclude that various tissues in the body
produce 1 ,25(OH)2D and utilize this hormone in a paracrine or
autocrine manner.
Although it remains debatable as to whether, in a nonpreg-
nant state, humans can produce 1 ,25(OH)2D extrarenally, there
is no question that in certain pathologic disorders, 1 ,25(OH)2D
is produced outside the kidney and that this aberrant synthesis
can cause alterations in calcium and bone metabolism. Approx-
imately 10% of patients with sarcoidosis have hypercalcemia
and up to 50% have hypercalciuria [58]. Several observations
have led to the conclusion that hypercalciuria and hypercalce-
mia can be caused by an unregulated metabolism of 25-OH-D3
by granulomatous tissue: (1) A bilaterally nephrectomized
patient with sarcoidosis had elevated circulating concentrations
of 1 ,25(OH)2D and hypercalcemia [59] (Fig. 7). (2) A hypopa-
rathyroid patient with sarcoidosis had elevated circulating
concentrations of 1 ,25(OH)2D [601. (3) Cultured pulmonary
alveolar macrophages [61] and lymph-node homogenates [47]
from sarcoid patients convert 25-OH-D3 to l,25(OH)2D3. Un-
regulated 25-OH-D3 metabolism also is the likely cause of
hypercalciuria and hypercalcemia in other chronic granuloma-
tous disorders, such as tuberculosis, silicosis, berylliosis, and
fungal diseases [23, 38, 62]. The mechanism by which granulo-
mas develop the capacity to produce 1 ,25(OH)2D3 is unknown.
But Reichel et al observed that cultured resting macrophages,
which are activated by either lipopolysaccharides from cell
walls of gram-negative bacteria or gamma interferon, metabo-
lize 25-OH-D3 to 1,25(OH)2D3. These authors suggest that
activated macrophages develop the machinery to carry out this
enzymatic process [63]. A few patients with Hodgkin's [64, 65]
•50 and non-Hodgkin's [66, 67] lymphoma who have hypercalcemia
also have elevated circulating concentrations of 1 ,25(OH)2D. It
.40 is likely that this calciotropic hormone also comes from an
extrarenal source. In one patient with an isolated splenic
lymphoma who had elevated serum concentrations of calcium30
_ and 1 ,25(OH)2D, the serum calcium and 1 ,25(OH)2D concen-
20 trations returned to normal after the tumor was removed.Finally, when cord blood lymphocytes were infected with
10 HTLV- 1, they metabolized 25-OH-D3 to 1 ,25(OH)2D3 [68]. Thisfinding suggests that this virus can, in some manner, induce
lymphocytes to produce this calciotropic hormone.
Biologic actions of] ,25-dihydroxyvitamin D3
Historically vitamin D has been recognized as a calcium-
regulating hormone responsible for maintaining serum calcium
concentrations in the normal range [14, 23, 36, 38]. When
1 ,25(OH)2D is synthesized in the kidney, it enters the circula-
tion and is transported on the vitamin D-binding protein to its
target tissues. The free form of the hormone enters the target
cell and, by a mechanism that is not well understood, it is
transported to the nucleus, where it interacts with its nuclear
receptor [69] (Fig. 8). The interaction of 1,25(OH)2D3 with its
receptor results in phosphorylation of the receptor complex,
which in turn interacts with the chromatin to activate transcrip-
tion of specific genes. In the small intestine, this interaction
results in the derepression of the gene for calcium-binding
protein (calbindin) [36]. However, in addition to stimulating
calbindin, 1 ,25(OH)2D3 influences the activities of several other
proteins including an alkaline phosphatase, a low-affinity Ca
ATPase, and a variety of brush-border proteins including actin
[26, 38, 70, 71] (Fig. 8). The net result is that 1,25(OH)2D3
stimulates intestinal absorption of calcium and phosphorus
from the diet.
It has long been recognized that vitamin D is important for
the development and maintenance of a healthy skeleton. There-
fore it has been assumed that 1 ,25(OH)2D3 directly affects the
ossification process. In the rat there is strong evidence, how-
ever, that 1 ,25(OH)2D3 is not essential for the normal develop-
ment and mineralization of bone. When serum calcium and
phosphorus were maintained in the normal range in vitamin
D-deficient rats, either by intravenous infusion of calcium and
phosphorus or by dietary manipulation, the results were the
same, that is, histologically the bones did not differ from those
of animals that received vitamin D [14, 72]. These observations
are further supported by the observation that infusion of
calcium into a child with vitamin D-dependent rickets type II
(who had been unresponsive to high doses of 1,25(OH)2D3 that
raised circulating concentrations of the hormone to 500 times
normal) healed the child's long-standing rickets [73]. Although
1 ,25(OH)2D3 does not appear to be absolutely essential for bone
ossification, osteoblasts possess nuclear receptors for the hor-
mone. In cultured rat osteosarcoma cells, 1 ,25(OH)2D3 stimu-
lates the synthesis of osteocalcin in a dose-dependent fashion
[74] and increases circulating concentrations of this bone-
derived protein in humans [75].
In keeping with its principal physiologic function of maintain-
ing calcium homeostasis, 1 ,25(OH)2D increases the removal of
calcium from bone. In response to small decreases in circulating
ionized calcium concentrations, V1'H secretion is stimulated.
Among its other actions in the kidney, PTH increases 1 ,25(OH)2D
c'tn.
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production and, in concert with 1 ,25(OH)2D, stimulates osteo-
clastic activity [76] (Fig. 5). At pharmacologic concentrations,
l,25(OH)2D3 can mobilize calcium from the bone without
assistance from PTH [77]. It remains unclear exactly how
I ,25(OH)2D3 stimulates bone calcium mobilization. Evidence is
mounting that 1 ,25(OH)2D3 does not directly stimulate osteoclas-
tic activity, especially in light of the observation that mature chick
osteoclasts do not possess nuclear receptors for 1 ,25(OH)2D3 [78].
Instead, 1 ,25(OH)2D appears to play a more fundamental role in
bone physiology by recruiting stem cells to become bone cells
[69] (Fig. 9). This hypothesis is based on the observation that
when cultured human peripheral monocytes that possess recep-
tors for I ,25(OH)2D3 are exposed to 1 ,25(OH)2D3, these cells
differentiate into multinucleated giant cells capable of mobiliz-
ing calcium-45 from cultured bone chips [791. These observa-
tions have led to the hypothesis that l,25(OH)2D3 does not
directly stimulate osteoclasts, but rather that this hormone
recruits undifferentiated stem cells in the bone marrow and
peripheral monocytes to become osteoclasts. When these cells
mature, they lose their nuclear receptors for 1 ,25(OH)2D3 and
are no longer influenced by the hormone. Instead, the mature
osteoclasts respond to PTH and other physiologic factors
including prostaglandins and growth factors. Although it is
intriguing to speculate that 1 ,25(OH)2D3 also might be respon-
sible for the recruitment of stem cells to form osteoblasts, no
evidence currently supports this concept. Therefore it is likely
that 1 ,25(OH)2D3 regulates the bone remodeling process that in
turn is essential for bone formation.
In 1980, a new concept regarding the physiologic actions of
1 ,25(OH)2D3 revolutionized our thinking about its biologic
actions. Stumpf and colleagues reported nuclear localization of
3H-l ,25(OH)2D3 in such diverse tissues as the gonad, stomach,
epidermis, hair follicle, pancreas, breast, kidney, parathyroid
gland, and thymus in vitamin-D deficient rats that had received
Inactivation of
24 OHase initiated 1,25(OH)2D3 hormone
catabolic cascade
(mitochondrial)
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a single intravenous dose of 3H-l,25(OH)2D3 [801. At first this
report was considered interesting but of little physiologic sig-
nificance. Since the initial observation, however, various labo-
ratories have reported that all these tissues, as well as periph-
eral monocytes, possess specific high-affinity, low-capacity
nuclear receptors for l,25(OH)2D3 [14, 36, 38, 63, 69].
Although the physiologic role of 1 ,25(OH)2D in these tissues
and cells remains to be determined, 1 ,25(OH)2D3 stimulates
calcium-binding protein synthesis in many of these tissues as
well as in certain regions of the brain including the cerebellum
[36, 63, 81]. In vitro, l,25(OH)2D3 inhibits human fibroblast and
keratinocyte proliferation [82, 83], stimulates terminal differen-
tiation of human keratinocytes [831, increases thyroid-stimula-
ting hormone synthesis, inhibits parathyroid hormone synthesis
[84], and induces monocytes to differentiate and produce inter-
leukin-l [63, 85]. When circulating resting T-lymphocytes are
activated with phytohemagglutinin, a I ,25(OH)2D3 receptor is
expressed, and the receptor-positive cells respond to the hor-
mone with decreasing proliferation and by inhibiting the pro-
duction of interleukin-2 [86]. When activated B-lymphocytes
are exposed to l,25(OH)2D3, immunoglobulin synthesis is in-
hibited [86].
A variety of tumor cells also possess nuclear receptors for
l,25(OH)2D3; when these cells are exposed to 1,25(OH)2D3 in
culture, the rate of proliferation is often decreased [87]. When
M-l (mouse leukemia) and HL-60 (human promyelocytic) cell
lines that possess receptors for 1,25(OH)2D3 are exposed to
I ,25(OH)2D3, there is a time- and dose-dependent induction of
cell-surface antigens including Fc and C-3 receptors, and lyso-
zyme and phagocytic activity [88, 89]. Most exciting is the
realization that these very malignant cells can be transformed
into what appear to be mature macrophages [88—90]. The fact
that certain clones of HL-60 cells, which.possess less than 10% of
the nuclear-binding activity for 1 ,25(OH)2D3, do not respond to
the hormone lends credence to the conclusion that I ,25(OH)2D3
influences the maturation of these cells by a specific, nuclear-
mediated mechanism [88, 90]. An important issue in these
studies, however, was whether the effect of 1,25(OH)2D3 on
these cells was permanent or transient. When 1 ,25(OH)2D3 was
added to cultured HL-60 cells, the hormone transformed these
cells into macrophages and (1) inhibited the expression of the
c-myc oncogene, (2) increased the expression of the monocyte-
specific cell-surface antigen 63D3, and (3) decreased the pro-
portion of cells in the S-phase of the replicative cycle [91].
These effects only continued as long as l,25(OH)2D3 was
present in the cultures, however. When 1,25(OH)2D3 was
removed, the mature mononuclear cells began to proliferate,
there was an increase in the expression of the c-myc oncogene,
and a decrease occurred in the expression of the 63D3 antigen
[91]. The multinucleated giant cells that also were present in the
cultures did not revert to immature forms after 1 ,25(OH)2D3
was withdrawn; this finding suggests that 1 ,25(OH)2D3 perma-
nently stabilized the cells' phenotype after they became multi-
nucleated.
These observations, and those regarding the effect of 1,25
(OH)2D3 on monocytes and lymphocytes, gave rise to specula-
tion that I ,25(OH)2D3 was an important immunoregulatory
hormone and that the hormone might be of value for treating
certain types of leukemia. Although 1 ,25(OH)2D3 prolongs the
survival of nude mice that have M-l promyelocytic leukemia
[87], the results of studies to treat human leukemias have been
disappointing [63]. The exact role of 1 ,25(OH)2D on the immune
system in vivo remains to be clarified. Vitamin D-deficient mice
have depressed inflammatory and phagocytic responses that are
restored when the animals or cells are treated with vitamin D
and l,25(OH)2D3 respectively [92]. Furthermore, peripheral
lymphocytes of patients with vitamin D-dependent rickets type
II do not develop receptors for 1 ,25(OH)2D3 upon mitogen
stimulation, and therefore the proliferation of these activated
cells is not inhibited by l,25(OH)2D3 [93]. Because patients with
vitamin D-dependent rickets type II as well as patients with
vitamin D deficiency have no overt evidence of immune defi-
ciency, 1 ,25(OH)2D3 probably is not essential for regulation of
the immune system.
The greatest clinical utility for I ,25(OH)2D3 might be for the
treatment of hyperproliferative disorders of the epidermis [94,
95]. Because l,25(OH)2D3 is extremely effective in inhibiting
the proliferation of human cultured keratinocytes and stimulat-
ing them to terminally differentiate [83, 94], we used the drug to
treat psoriasis. A disease that afflicts approximately 1% to 3%
of the world's population, psoriasis is caused by hyperprolifera-
tion of the germ cells of the epidermis. We surmised that if
1 ,25(OH)2D3 could inhibit the proliferation of human keratino-
cytes in vitro, the same effect would be elicited in vivo, and we
anticipated that the psoriasis would improve. Psoriatic patients
who have had the disease for at least 5 years received 1,25
25(OH)2D3 by oral or topical administration. Seventy-five per-
cent of the patients with moderate to severe psoriasis who were
treated with orally administered 1 ,25(OH)2D3 showed moderate
to substantial clearing of the hyperkeratotic plaques and central
clearing in their lesions while they were taking the drug (Fig.
10). Three patients who received topical 1,25(OH)2D3 dramati-
cally improved after 2 to 4 weeks of treatment (Smith E, Pincus
S, Holick MF, unpublished results). One of the major concerns
about using this calciotropic hormone for treating leukemias,
lymphomas, and psoriasis is its great potential for causing
hypercalciuria and hypercalcemia. We have found that by
giving the hormone at night just before bedtime, we could
increase the dose up to 2.0 jig/day without inducing hypercal-
ciuria or hypercalcemia (Smith E, Pincus S, Holick MF, un-
published results). Therefore, 1 ,25(OH)2D3 and its analogues
have great promise as therapeutic agents for the treatment of
such diverse disorders as renal osteodystrophy [96], leukemih,
myelofibrosis, and psoriasis [63, 94, 95].
Regulation of parathyroid hormone secretion by
I ,25-dihydroxyvitamin D3
One of the major issues that confronts a patient with chronic
renal failure is decreased production of 1,25(OH)2D3 by the
diseased kidneys and the attendant hyperphosphatemia that
also inhibits l,25(OH)2D3 synthesis. As a result of the decrease
in circulating concentrations of 1 ,25(OH)2D, the small intestine
is unable to efficiently absorb dietary calcium. The net result is
a transient decrease in ionized calcium and an increase in the
secretion and production of PTH. If the cycle is not interrupted,
severe secondary hyperparathyroidism and osteodystrophy oc-
cur. Long-standing speculations that vitamin-D metabolites
might influence the production and secretion of PTH [38, 97]
now are justified by firm evidence that the cells of the parathy-
roid gland possess specific nuclear receptors for 1 ,25(OH)2D3
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Hg. 10. Effect of oral administration of 1,25(OH)2D3 on psoriatic patient. This female has had psoriasis for 4 years. Photographs were taken of
her legs prior to treatment (A) and after 3 months of receiving a daily oral dose of 2.0 jsg of I ,25(OH)2D3 (B). There was a substantial decrease in
erythema and clearing of lesions after treatment with I ,25(OH)2D3.
[98]. Unfortunately, early studies that evaluated the effect of
1 ,25(OH)2D3 on PTH secretion in rodents and dogs were
confusing; in some studies 1 ,25(OH)2D3 caused an increase in
PTH secretion, whereas in others 1 ,25(OH)2D3 caused a de-
crease or had no effect on the production of PTH. When
cultured bovine parathyroid cells were exposed to 1 ,25(OH)2D3
for 24 hours, preproparathyroid hormone mRNA concentra-
tions were suppressed [84]. Whether this suppression was due
to a direct effect of 1 ,25(OH)2D3 on the PTH gene or was an
indirect effect due to its inhibition on the proliferation of the
cultured parathyroid cells remains to be determined. In addi-
tion, Slatopolsky and coworkers reported that whereas oral
administration of I ,25(OH)2D3 to dialysis patients did little to
depress circulating concentrations of immunoreactive PTH,
intravenous administration of 1 ,25(OH)2D3 had a pronounced
effect on suppressing circulating PTH levels [98] (Fig. 11).
Despite the fact that 1 ,25(OH)2D3 also increased circulating
concentrations of ionized calcium, an increase that itself would
suppress PTH secretion, these investigators found that the
increases in ionized calcium concentrations could not fully
account for the marked effect that 1 ,25(OH)2D3 had on serum
PTH concentrations 198]. Furthermore, when patients were
given calcium carbonate to increase serum calcium concentra-
tions, the decrement in serum iPTH was only 25.0 6.0% when
compared with 73.5 5.0% for the group that received 1,25
(OH)2D3 intravenously. Thus the transient, high circulating
concentrations of 1 ,25(OH)2D3 that are achieved when the drug
is given intravenously might have a direct pharmacologic action
on suppressing secondary hyperparathyroidism in dialysis pa-
tients.
Clinical utility of the vitamin D and
vitamin D metabolite assays
It is often perplexing to determine which vitamin D assays
should be used when evaluating patients with disorders of
Fig. 11. Temporal relationships between ionized calcium and serum
i-PTH before, during, and after intravenous l,25(OH)2D3 administra-
tion in patients with moderate hyperparathyroidism. The maximum
decrement in i-PTH was 73.5%. In the first 3 weeks of treatment with
1 ,25(OH)2D3, there was no change in ionized calcium: however, serum
i-PTH decreased from 132 + 20 to 90 + 20 xlEq/ml. (From Ref. 98.)
calcium and bone metabolism. Specific and sensitive assays
have been developed for the measurement of circulating con-
centrations of vitamin D, 25-OH-D, 24,25(OH)2D, and 1,25
(OH)2D. Measurement of the circulating concentrations of
vitamin D are of little value, because the normal range can vary
from undetectable to as much as 100 ng/ml, depending on the
dietary and supplemental intake of vitamin D and the most
recent exposure to sunlight [10]. However, this assay might
prove valuable for determining whether a patient can absorb
dietary or supplemental vitamin D. Twelve hours after a single
oral dose of 50,000 IU (1.25 mg) of vitamin D2, the blood
concentration of vitamin D can be expected to increase from a
baseline value of less than 5 ng/ml to up to 60 10 ng/ml [99]
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Fig. 12. Serum vitamin D concentrations in 7 patients with intestinal fat
ma/absorption syndromes after a single oral dose of 50,000 IU (1.25
mg) of vitamin D2. For comparison, the means and standard errors of
vitamin D concentrations measured in 7 normal control subjects after a
similar dose are indicated by the closed circles and dotted lines
(- -S- - -). Note that 2 patients, one with Crohn's ileocolitis (patient F)
and one with ulcerative colitis (patient G), had essentially normal
absorption curves. Five patients, however, showed a dramatic lack of
response, with no values above 10 ng/ml. (From Ref. 99.)
(Fig. 12). For patients with fat malabsorption syndromes, the
peak value is usually less than 10 ng/ml.
The most useful assay for determining the vitamin D status of
a patient is measurement of the circulating concentration of
25-OH-D. The circulating half-life of this metabolite is about 3
weeks, and its concentration is an excellent reflection of cumu-
lative dietary and supplemental intake of vitamin D2 and
vitamin D3 as well as exposure to sunlight [10, 381. Although the
normal range for circulating concentrations of 25-OH-D varies
from one laboratory to another, the range is usually between 8
and 55 ng/ml [23, 38, 100]. During the summer, lifeguards and
sunbathers often have concentrations as high as 120 ng/ml
without any untoward side effects on calcium metabolism. The
25-OH-D levels are often low in patients with severe chronic
liver disease or intestinal fat malabsorption syndromes and in
house-bound or institutionalized elderly individuals [10, 38].
The hallmark of vitamin D intoxication is a markedly elevated
concentration of 25-OH-D (usually > 200 ng/ml).
The assay for l,25(OH)2D has been extremely useful in
evaluating disorders of calcium and bone metabolism caused by
acquired or inborn errors in either the metabolism of 25-OH-D
to 1 ,25(OH)2D3 or the lack of recognition of 1 ,25(OH)2D by its
target tissues (Table I). The circulating half-life of 1 ,25(OH)2D
is approximately 4 to 6 hours, and the normal range, which can
vary from laboratory to laboratory, is usually about 25 to 65
pg/nil [23, 38, 100]. In patients with renal insufficiency, circu-
lating concentrations of 1 ,25(OH)2D are normal until the GFR is
less than about 30% of normal or if hyperphosphatemia is
present [381. The assay is useful in differentiating between
vitamin D-dependent rickets types I and II because patients
Table 1. Serum concentrations of la,25(OH)2D in disorders of
calcium, phosphorus, and bone metabolisma
Disease states Serum la,25(OH)2D
Vitamin D deficiency
Renal failure
GFR> 30 ml/min/l.7 m2 or N
GFR < 30 ml/min/l.7 m2
Hypoparathyroidism or N
Pseudohypoparathyroidism or N
Vitamin D-dependent rickets
Typel
Type II orN
X-linked vitamin D-resistant
rickets or N
Tumor-induced osteomalacia
Oncogenic hypercalcemia
Some lymphomas C
Hyperparathyroidism or N
Sarcoidosis, tuberculosis,
silicosis j or N
Idiopathic hypercalciuria N or C
Williams syndrome C
Vitamin D intoxication C or N
a Data from Ref. 23.
with the former illness have an inborn defect in the renal
synthesis of I ,25(OH)2D and therefore the levels of the hor-
mone are low, whereas in the latter patients l,25(OH)D con-
centrations are extremely high because of end-organ resistance
to the hormone [23, 38, 101]. Henneman, Dempsey, Carroll,
and Albright first suggested that the hypercalcemia associated
with sarcoidosis was due to a hypersensitivity of the intestine to
vitamin D [102]. It now has been shown that patients with
sarcoidosis and other chronic granulomatous disorders, who
have hypercalciuria and/or hypercalcemia, often have high
normal or elevated circulating concentrations of 1 ,25(OH)2D
[23, 38, 103]. Patients with primary hyperparathyroidism usu-
ally have high normal or elevated circulating concentrations of
1 ,25(OH)2D3, whereas patients with hypercalcemia due to a
tumor often have low-normal or reduced concentrations [104].
In a few case reports, hypercalcemic patients with lymphoma
had elevated concentrations of 1 ,25(OH)2D [64—66].
The 24,25(OH)2D assay principally has been used for clinical
research and is of little clinical value. The normal circulating
concentration of this metabolite is about 1 to 4 ng/ml.
Conclusion
The kidney plays a pivotal role in the regulation of calcium
and phosphorus metabolism directly by regulating tubular re-
absorption of calcium and phosphorus and indirectly by gener-
ating 1 ,25(OH)2D. This hormone is released into the circulation
and travels to the small intestine to stimulate intestinal calcium
and phosphate absorption and to bone to mobilize calcium and
phosphorus. Although 1 ,25(OH)2D does not appear to be abso-
lutely essential for the development and maintenance of the
skeleton, its role in recruiting and stimulating precursor bone
cells to mature probably is important for the long-term health of
the mammalian skeleton. When the reserve capacity of the kidney
is compromised to the extent that quantities of 1 ,25(OH)2D
generated are insufficient to maintain calcium homeostasis,
----I
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secondary hyperparathyroidism and osteodystrophy often re-
sult. Treatment of these patients with 1 ,25(OH)2D3 or one of its
analogues (1 a-hydroxyvitamin D3 or dihydrotachysterol) often
corrects the calcium imbalance [23, 38, 961. These compounds
can correct calcium imbalance by increasing intestinal calcium
absorption and possibly by inhibiting PTH secretion. Intrave-
nous or possibly topical preparations of I ,25(OH)2D3 might be
better than oral preparations because transient high levels of
1 ,25(OH)2D3 might not only increase intestinal calcium absorp-
tion but also might depress PTH synthesis and recruit stem cells
for bone remodeling and mineralization.
The recent revelations that most tissues and cells in the body
recognize and respond to 1 ,25(OH)2D have opened a new
chapter for the physiologic role of this renal hormone. Although
it is doubtful that 1 ,25(OH)2D is absolutely essential for normal
functioning of the endocrine and immune systems, the fact that
the skin, pancreas, gonads, pituitary gland, and brain can
respond to this renal hormone suggests the possibility that we
can develop analogues of 1 ,25(OH)2D3 that are effective in
regulating cell growth and activity but devoid of activity on
calcium metabolism. Preliminary results demonstrating that
1 ,25(OH)2D3 is an effective and safe treatment for psoriasis
herald a new era for the pharmacologic use of 1 ,2S(OH)2D3 and
its analogues in the treatment of a variety of hyperproliferative
disorders.
Questions and answers
DR. JEROME P. KA55IRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center, Boston,
Massachusetts): What factor is more important in the patho-
genesis of the hypocalcemia of chronic renal failure, the in-
crease in serum phosphorus or the decrease in intestinal cal-
cium absorption?
DR. HOLIcK: Although it is possible to raise the serum
concentration of phosphate to a level high enough to cause the
precipitation of calcium and phosphate into soft tissues, it is
likely that in patients with progressive renal failure, the inhib-
itory effect of hyperphosphatemia on the renal 25-OH-D- 1—
hydroxylase is the more important cause of the hypocalcemia.
Patients with mild to moderate renal insufficiency have enough
25-OH-D- 1—hydroxylase activity to maintain calcium homeo-
stasis. However, if their phosphorus metabolism is not con-
trolled, a small elevation in the circulating concentration of
phosphorus will depress the renal production of 1 ,25(OH)2D.
As a result, the intestine is less efficient in absorbing dietary
calcium. This effect can cause hypocalcemia and secondary
hyperparathyroidism. For patients with moderate to severe
renal insufficiency, the reserve capacity of the kidney to pro-
duce 1 ,25(OH)2D is compromised. Correction of the serum
phosphorus to normal will not result in a significant increase in
circulating concentrations of 1 ,25(OH)2D. These patients will
benefit from therapy with either 1 ,25(OH)2D3 or dihydrotachy-
sterol (DHT).
DR. VINCENT J. CANzANELLO (Division of Nephrology, New
England Medical Center): How early in renal failure should one
use 1 ,25-dihydroxyvitamin D3 to prevent the early signs of renal
osteodystrophy? Also, what assays of PTH do you use to
monitor the therapeutic effect of 1 ,25(OH)2D3 in patients with
mild, moderate, or chronic renal failure?
DR. HOLICK: To answer your first question, I believe that it is
important to monitor circulating concentrations of phosphorus,
1 ,25(OH)2D, and immunoreactive PTH. If the circulating con-
centrations of phosphorus are normal and the 1 ,25(OH)2D3 levels
are decreasing in the presence of increasing concentrations of
PTH, it is reasonable to institute therapy with 1 ,25(OH)2D3 or
dihydrotachysterol. I usually use 1 ,25(OH)2D3 and begin with
0.25 tg once daily and increase the dosage in increments of 0.25
g with careful monitoring of serum calcium and phosphorus
concentrations. Regarding your second question, I use the
N-terminal or mid-molecule assay for PTH. The C-terminal
assay is not useful because the kidneys normally excrete the
biologically inactive C-terminal fragment of PTH, and therefore
patients with renal insufficiency often have markedly elevated
circulating concentrations of the C-terminal fragment. The
N-terminal or mid-molecule assays provide information about
the biologically active portion of PTH that is present in the
circulation.
DR. KA55IRER: How are the plasma levels of the various
vitamin D metabolites best used in diagnosis and therapy?
DR. HOLICK: The assays for the determination of 25-hydroxy-
vitamin D (25-OH-D) and 1,25 dihydroxyvitamin D [1 ,25(OH)2D]
are the only assays that are of clinical importance. The 25-OH-
D assay is most useful for determining the overall vitamin D
status of a patient. The normal range is usually between 8 and
55 ng/ml. A value below about 10 nglml often suggests that the
patient is becoming or is vitamin D deficient. It is a misconcep-
tion that the serum calcium must be low to make a diagnosis of
vitamin D deficiency. Early in the course of vitamin D defi-
ciency, PTH secretion increases, accompanied by increases in
the renal production of 1 ,25(OH)2D, tubular reabsorption of
calcium, and the tubular excretion of phosphorus. The net
result is that a patient with marginal vitamin D deficiency often
has normal circulating concentrations of calcium, normal or
high concentrations of 1 ,25(OH)2D, low or low-normal concen-
trations of phosphorus, and elevated concentrations of PTH.
The 25-OH-D assay is most useful for detecting vitamin D
deficiency in patients with chronic hepatic failure, nephrotic
syndrome, or intestinal malabsorption syndromes. In addition
the elderly, especially those who do not go outdoors very often,
should have their serum 25-OH-D checked once a year, because
there is substantial evidence that vitamin D deficiency can
increase their risk of hip fracture.
The 1 ,25(OH)2D assay is most useful for evaluating disorders
in calcium and bone metabolism that are related to acquired or
inherited defects in (I) vitamin D metabolism or (2) target tissue
recognition of 1 ,25(OH)2D3.
DR. PAUL KURTIN (Chief, Division of Pediatric Nephrology,
New England Medical Center): Does vitamin D supplementa-
tion increase growth in children who have severe renal disease?
Also, do children with nephrotic syndrome who drink a lot of
milk get adequate quantities of vitamin D?
DR. HOLICK: Since the l940s it has been well documented
that children and adults with severe renal disease become
resistant to physiologic doses of vitamin D and that pharmaco-
logic doses often correct the bone and calcium abnormalities. It
is now appreciated that vitamin D must be metabolized in the
liver and then the kidney before it becomes biologically active.
In chronic renal disease, the kidney is unable to produce
adequate quantities of 1 ,25(OH)2D. However, when pharmaco-
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logic doses of vitamin D are given to these patients, their serum
25-OH-D concentrations increase into the high-normal or high
range (usually greater than 50 nglml). It is believed that the
1 ,25(OH)2D receptor will recognize 25-OH-D when the circu-
lating concentrations of this metabolite are elevated. Therefore,
although pharmacologic doses of vitamin D are sometimes
effective, it should be noted that vitamin D is stored in the fat of
the body and over time can lead to vitamin D intoxication. The
circulating half-lives of 1 ,25(OH)2D3 and DHT are approxi-
mately 6 hours and 2 to 3 weeks respectively and are more
effective than 25-OH-D3 in increasing intestinal calcium trans-
port and correcting the calcium and bone disturbances that
confront patients with severe renal insufficiency.
Children with nephrotic syndrome who excrete more than 4 g
of protein in their urine each day are prone to develop vitamin
D deficiency. As I noted earlier, the major reason for this
consequence is that the vitamin D-binding protein, which has
25-OH-D tightly bound to it, is excreted along with albumin in
the urine. Therefore these children often require an increased
intake of vitamin D. The recommended daily allowance for
children is 400 IU or 10 pg of vitamin D each day. In the United
States, one quart of milk contains 400 IU of vitamin D. In
children with severe proteinuria, it has been recommended that
the intake of vitamin D be increased tenfold. If the child does
not obtain vitamin D3 from exposure to sunlight, he or she
would theoretically have to drink 10 quarts of milk each day to
obtain enough vitamin D to compensate for the loss of 25-OH-D
in the urine. The best method of managing these patients is to
follow their circulating concentrations of 25-OH-D. If the level
is slowly declining, I would increase the vitamin D intake with
a vitamin D supplement (usually one multivitamin pill that
contains 400 IU of vitamin D2). If the serum 25-OH-D concen-
tration continues to decline, then a supplement of 50,000 IU of
vitamin D once every one to two weeks may be needed. For
these patients, I like to have their circulating concentration of
25-OH-D in the mid-normal range of about 25 to 45 ng!ml.
DR. KASSIRER: If a patient has renal osteodystrophy with
osteomalacia as its predominant component, under what cir-
cumstances should vitamin D be given?
DR. HOLICK: If the 25-OH-D concentration is normal, and
osteomalacia persists, further evaluation should be considered.
If the circulating concentration of 1 ,25(OH)2D is low at a time
that the fasting phosphorus is normal, vitamin D deficiency is
likely and a trial of 1 ,25(OH)2D3 may be appropriate. Finally, it
has been suggested that aluminum deposition at the calcification
front causes a 1 ,25(OH)2D-resistant osteomalacia. Serum con-
centrations of aluminum can be measured, and a double tetra-
cyline-labeled bone biopsy is of value to determine whether
aluminum deposits are present in the bone and whether bone
formation has been impaired.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): How do oral and
intravenous administration of 1 ,25(OH)2 vitamin D increase the
efficiency of intestinal calcium absorption?
DR. H0LIcK: When 1 ,25(OH)2D3 is given orally, some of the
hormone is absorbed into the portal and lymphatic systems,
whereas the remainder probably is taken up by the intestinal
absorptive cells. After 1,25(OH)2D3 enters the intestinal cells, it
is translocated to the nucleus, where it binds to a nuclear
receptor that in turn sets off a chain of events leading to new
protein synthesis and an increase in intestinal calcium absorp-
tion. When the drug is given intravenously, it is transported to
the small intestine on the vitamin D-binding protein and enters
the intestinal cells from the serosal side. The major difference
between the two methods of delivery is that, when the drug is
given orally, pharmacologic concentrations are immediately
made available to the principal target tissue, the small intestine,
whereas when the drug is given intravenously, the 1 ,25(OH)2D3
is presented to the small intestine at lower concentration and in
a more physiologic manner.
DR. CANZANELLO: Is 24,25 vitamin D of value in treating
osteomalacia?
DR. H0LIcK: The physiologic importance of 24,25(OH)3
remains unclear. It has been reported that this metabolite
increases bone formation in chickens, induces protoglycan syn-
thesis in cultured growth plate chondrocytes, and promotes bone
mineralization in humans when combined with 1 ,25(OH)2D3 to a
greater degree than 1 ,25(OH)2D3 could by itself. To date there
has not been a clear demonstration that 24,25(OH)2D3 is of
value in treating osteomalacia.
DR. KASSIRER: In the elderly patient who has chronic renal
failure but who is not on dialysis, under what circumstances do
you institute therapy with phosphate binders? My concern
focuses on side effects, such as constipation, as well as on
patient noncompliance when they are instructed to take phos-
phate binders with every meal.
DR. HOLIcK: Strong evidence exists that elevated circulating
concentrations of phosphorus can depress the renal production
of I ,25(OH)2D3. For patients with moderate renal insufficiency,
the associated elevated concentrations of phosphorus can fur-
ther decrease the production of 1 ,25(OH)2D3 in kidneys that are
already compromised and have a decreased reserve capacity to
produce this hormone. For the elderly, who already have an
age-related decrease in their ability to absorb dietary calcium,
the inhibitory effect of phosphate on the renal production of
1 ,25(OH)2D3 may accelerate their age-related bone loss to a
greater degree. Thus, accelerated osteoporosis with concomi-
tant renal osteodystrophy could increase their risk of fracture.
I believe that the judicious use of phosphate binders under these
circumstances is reasonable. Recently Slatopoisky reported
that large doses of calcium carbonate (up to 17 g) could be
safely used as a phosphate binder without causing significant
constipation [1051. Therefore, I would control the circulating
concentrations of phosphorus with a phosphate binder to pre-
serve the renal production of 1 ,25(OH)2D3.
DR. KASSIRER: I would be less of an interventionist. Effective
therapy with phosphate binders can produce a substantial
reduction in the quality of life. In addition, the eldery are likely
to derive little or no benefit from such therapy.
DR. H0LIcK: I agree that phosphate binders can be an
inconvenience for the patient. Let me quantify my answer. I
would carefully follow the patient's circulating concentrations
of PTH, l,25(OH),D, calcium, and phosphorus. I would use a
phosphate binder only if I saw that there was a steady decline in
1,25(OH)2D levels and a steady rise in PTH levels. Otherwise I
would not.
DR. HARRINGTON: At what point do you begin to treat the
patient who has progressive renal failure and increasing para-
thyroid hormone levels? In theory, if you wait too long, you
might not be able to reverse the hyperplasia. Conversely, if you
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treat too aggressively and induce hypercalcemia, the rate of
renal insufficiency may accelerate.
DR. H0LIcK: For patients with progressive renal failure, the
eventual outcome will be a decrease in the renal production of
l,25(OH)2D, which causes a decrease in the efficiency of
intestinal calcium absorption and a compensatory rise in the
circulating concentrations of PTH. Initially it is reasonable to
provide the patient with calcium carbonate. This treatment can
serve two functions: it acts as a phosphate binder and increases
the amount of calcium in the intestine. Because the efficiency of
intestinal calcium transport is often decreased in these patients,
the increase in the amount of calcium in the intestine may help
compensate for this defect. However, when the renal produc-
tion of 1 ,25(OH)2D is compromised to the degree that the body
can no longer satisfy its calcium requirement, then 1 ,25(OH)2D3
or DHT therapy should be considered. The drugs will enhance
the efficiency of intestinal calcium absorption. Therefore care-
ful and frequent monitoring of serum calcium and phosphorus is
recommended to avoid hypercalcemia, hyperphosphatemia,
and nephrocalcinosis.
DR. KURTIN: We know that the active form of vitamin D, at
least in vitro, has an effect on the immune system. Does vitamin
D deficiency play a causal role in infections in nephrotic
children?
DR. HoLIcK: There is mounting evidence that under experi-
mental conditions l,25(OH)2D3 has effects on the immune
system. For example, peritoneal macrophages from vitamin
D-deficient rats are not as effective in phagocytozing yeast
cells. In-vitro resting lymphocytes do not possess receptors for
l,25(OH)2D3. However, when these lymphocytes are activated,
they develop receptors for the hormone. In activated T lym-
phocytes, 1 ,25(OH)2D3 decreases interleukin-2 production, and
in activated B lymphocytes immunoglobulin production is de-
creased. The physiologic importance of 1 ,25(OH)2D3 on the
immune system is unknown. Patients with vitamin D deficiency
and vitamin D-dependent rickets type I who have a deficiency
of 1 ,25(OH)2D3 have competent immune systems. Therefore,
although it is unlikely that vitamin D deficiency is the cause of
infection in children with nephrotic syndrome, it might be a
contributing factor.
DR. KASSIRER: Is the increase in parathyroid hormone in
patients with secondary hyperparathyroidism from renal failure
simply due to the decrease in serum calcium levels, or is it also
related to a decrease in 1 ,25(OH) vitamin D?
DR. H0LIcK: It may be the consequence of a combination of
both effects. Clearly any decrease in ionized calcium concen-
tration results in a compensatory increase in PTH secretion.
There is evidence that the parathyroid gland possesses recep-
tors for 1 ,25(OH)2D3 and that this hormone can decrease the
expression of the PTH gene in vitro. In vivo, Slatopolsky has
shown that intravenous administration of 1 ,25(OH)2D3 can
decrease PTH concentrations to a greater degree than can be
accounted for by the subsequent rise in ionized calcium con-
centrations. Whether the effect of 1 ,25(OH)2D3 on PTH synthe-
sis and secretion is a physiologic or pharmacologic event is
unknown. It is likely that the major effect of 1,25(OH)2D is to
increase ionized calcium concentrations and that it also may
directly modulate PTH secretion to a lesser degree.
DR. KASSIRER: Does administration of calcium carbonate
suppress hyperparathyroidism?
Da. HOLICK: Calcium carbonate can suppress secondary
hyperparathyroidism by two mechanisms. First, an increase in
dietary calcium may help compensate for the decrease in the
efficiency of intestinal calcium transport that is caused by a
decrease in the renal synthesis of 1 ,25(OH)2D. Second, calcium
carbonate can bind dietary phosphate and prevent its absorp-
tion into the circulation. Because high circulating concentra-
tions of phosphate can inhibit the renal synthesis of
1 ,25(OH)2D, the maintenance of a normal serum phosphorus
level should permit the kidney to produce 1 ,25(OH)2D to the
best of its ability.
DR. KASSIRER: It is important to recognize that patients with
renal disease who absorb calcium poorly can nonetheless
become hypercalcemic readily when they are given sufficient
calcium carbonate therapeutically.
DR. HOLICK: That is correct. These patients often have poor
bone formation rates. As a result, the small amount of the
calcium that is absorbed by the intestine cannot be deposited in
the bone. Because these patients are unable to excrete the
calcium in the urine, the calcium remains in the circulation.
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